No Data
Sarepta Therapeutics Announces Leadership Change and Equity Deal
Oppenheimer Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)
Sarepta Therapeutics, Arrowhead Pharmaceuticals Ink Collaboration, Licensing Deal
Express News | Sarepta: Co Will Nominate & Arrowhead Will Deliver Ind-Ready Constructs for 6 Targets Across Skeletal Muscle, Cardiac, CNS
Express News | Sarepta Therapeutics Inc - CEO Doug Ingram to Join Arrowhead Board
Express News | Sarepta Therapeutics Inc - Approves $500 Million Share Repurchase Authorization